Your browser is no longer supported. Please, upgrade your browser.
CBLI [NASD]
Cleveland BioLabs, Inc.
Index- P/E- EPS (ttm)-0.19 Insider Own50.26% Shs Outstand13.28M Perf Week-15.12%
Market Cap69.34M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float5.24M Perf Month-22.07%
Income-2.40M PEG- EPS next Q- Inst Own4.00% Short Float1.73% Perf Quarter-32.17%
Sales0.30M P/S231.14 EPS this Y17.40% Inst Trans- Short Ratio0.29 Perf Half Y42.94%
Book/sh-0.22 P/B- EPS next Y- ROA-83.50% Target Price- Perf Year121.90%
Cash/sh0.15 P/C31.52 EPS next 5Y- ROE86.40% 52W Range1.43 - 10.97 Perf YTD35.07%
Dividend- P/FCF- EPS past 5Y35.90% ROI86.20% 52W High-57.53% Beta0.69
Dividend %- Quick Ratio7.60 Sales past 5Y-37.30% Gross Margin- 52W Low225.87% ATR0.48
Employees2 Current Ratio7.60 Sales Q/Q-100.00% Oper. Margin- RSI (14)39.14 Volatility12.28% 8.71%
OptionableYes Debt/Eq- EPS Q/Q16.40% Profit Margin- Rel Volume0.39 Prev Close4.52
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume310.35K Price4.66
Recom- SMA20-10.79% SMA50-17.44% SMA20019.27% Volume120,006 Change3.10%
Jan-24-14Downgrade Oppenheimer Outperform → Perform
Mar-21-13Initiated Cantor Fitzgerald Buy $4
Dec-06-12Initiated Oppenheimer Outperform $3
Dec-04-12Initiated Burrill Institutional Research Mkt Outperform $4
Feb-02-11Initiated Wedbush Outperform $10
Oct-13-10Downgrade WBB Securities Strong Buy → Hold $6.50 → $6.50
Sep-17-10Reiterated Rodman & Renshaw Mkt Outperform $8 → $11
Jul-21-10Downgrade WBB Securities Strong Buy → Speculative Buy $6.50
Sep-29-09Initiated Rodman & Renshaw Mkt Outperform $8
Apr-14-21 08:00AM  
Apr-09-21 03:05PM  
Apr-02-21 02:52PM  
Mar-26-21 02:10PM  
Mar-19-21 03:42PM  
Mar-12-21 03:31PM  
Feb-25-21 09:51PM  
Feb-24-21 02:45PM  
Feb-23-21 04:30PM  
Feb-19-21 01:30PM  
Feb-17-21 04:15PM  
04:15PM  
01:22PM  
Feb-16-21 05:57PM  
Jan-30-21 07:06PM  
Jan-27-21 05:32PM  
Jan-20-21 04:05PM  
Jan-05-21 09:28AM  
Jan-03-21 02:20PM  
Jan-02-21 07:30AM  
Dec-28-20 09:15PM  
08:07PM  
Dec-26-20 10:05AM  
Dec-22-20 07:35AM  
Dec-19-20 02:15PM  
Dec-17-20 11:11PM  
11:02PM  
Dec-09-20 01:58PM  
Dec-03-20 06:01PM  
Dec-02-20 01:52PM  
Nov-24-20 03:50PM  
Nov-23-20 08:31PM  
Nov-20-20 09:28PM  
Nov-13-20 06:59PM  
12:27PM  
Nov-12-20 01:31PM  
Nov-11-20 03:18PM  
Nov-10-20 06:00AM  
Nov-07-20 02:40PM  
Nov-06-20 10:16PM  
09:43AM  
09:18AM  
Nov-04-20 05:13PM  
10:55AM  
Nov-03-20 05:46PM  
01:16PM  
Oct-31-20 07:15PM  
Oct-29-20 07:40PM  
10:30AM  
Oct-27-20 05:05PM  
01:53PM  
10:15AM  
Oct-26-20 03:33PM  
02:52PM  
02:45PM  
01:42PM  
Oct-24-20 02:10PM  
Oct-23-20 04:45PM  
Oct-22-20 05:45PM  
Oct-21-20 10:20PM  
08:54PM  
02:33PM  
12:52PM  
10:45AM  
10:10AM  
08:30AM  
08:04AM  
Oct-20-20 06:51PM  
06:21PM  
01:44PM  
10:50AM  
08:30AM  
08:17AM  
Oct-19-20 04:05PM  
Jun-03-20 04:05PM  
Jun-01-20 08:30AM  
May-15-20 09:00AM  
Jan-28-20 07:53AM  
07:12AM  
Nov-18-19 06:58AM  
Nov-14-19 04:30PM  
Oct-04-19 10:25AM  
Aug-20-19 01:40PM  
Aug-14-19 08:30AM  
Jun-12-19 10:30AM  
May-25-19 08:15AM  
May-15-19 08:30AM  
Mar-07-19 08:15AM  
Feb-07-19 11:58AM  
Dec-14-18 02:22PM  
Dec-06-18 09:31AM  
Nov-23-18 07:20AM  
Nov-14-18 07:30AM  
Oct-05-18 01:24PM  
Aug-14-18 05:15PM  
04:45PM  
Aug-06-18 05:00PM  
Jun-22-18 03:12PM  
Jun-12-18 07:30AM  
May-31-18 04:18PM  
Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and immuno-oncology. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand; and CBL0137, a small molecule with a multi-targeted mechanism for the treatment of various types of cancer. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, Rusnano, and Everon Biosciences. The company was incorporated in 2003 and is headquartered in Buffalo, New York.